TABLE 2.
Clinical indications, pathogens, and dosing strategies
| Clinical indicationsa | Value N = 40 |
|---|---|
| ABSSTI | 18 (45%) |
| BSI | 27 (67.5%) |
| Osteomyelitis | 16 (40%) |
| IE | 4 (10%) |
| Septic arthritis | 4 (10%) |
| Pathogensb | |
| MRSA | 23 (57.5%) |
| MSSA | 12 (30%) |
| Streptococcus species | 7 (17.5%) |
| CoNS | 5 (12.5%) |
| Enterococcus species | 1 (2.5%) |
| Dalbavancin dosing strategies | |
| 1,500 mg IV once | 27 (67.5%) |
| 1,125 mg IV oncec | 1 (2.5%) |
| 1,500 mg IV weekly ×2 dosesd | 12 (30%) |
| Outpatient dosese | 13 (32.5%) |
a
ABSSTI, acute bacterial skin and soft tissue infection; BSI, bloodstream infection; IE, infective endocarditis; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; CoNS, coagulase negative staphylococcus; IV, intravenous.
b
11 or 27.5% of patients had polymicrobial infections.
c
Renally adjusted dosing.
d
Given on day 1 and day 8.
e
Four patients were treated in the outpatient setting only.